Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity

v3.22.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Preferred Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Non-Controlling Interest
Beginning balance (in shares) at Mar. 31, 2019   81,460,724 100,000 758,125        
Beginning balance at Mar. 31, 2019 $ 36,358 $ 10 $ 100 $ (71) $ 332,793 $ (356) $ (296,118) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 13,900           13,900  
Foreign currency translation (235)         (235)    
Settlement of derivative liability 17,588       17,588      
Stock-based compensation expense 3,353       3,353      
Shares issued:                
Exercise of stock options (in shares)   2,279,266            
Exercise of stock options 3,865       3,865      
Vesting of restricted and performance stock units (in shares)   123,943            
Exercise of warrants (in shares)   3,283,090            
Exercise of warrants 2,625       2,625      
Ending balance (in shares) at Mar. 31, 2020   87,147,023 100,000 758,125        
Ending balance at Mar. 31, 2020 77,454 $ 10 $ 100 $ (71) 360,224 (591) (282,218) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 54,884           54,884  
Foreign currency translation (312)         (312)    
Stock-based compensation expense 5,877       5,877      
Shares issued:                
Exercise of stock options (in shares)   2,506,383            
Exercise of stock options 7,209       7,209      
Vesting of restricted and performance stock units (in shares)   136,680            
Ending balance (in shares) at Mar. 31, 2021   89,790,086 100,000 758,125        
Ending balance at Mar. 31, 2021 145,112 $ 10 $ 100 $ (71) 373,310 (903) (227,334) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 35,569           35,546 23
Foreign currency translation (39,395)         (38,438)   (957)
Stock-based compensation expense $ 19,970       19,970      
Shares issued:                
Exercise of stock options (in shares) 1,312,460 1,311,098            
Exercise of stock options $ 4,300       4,300      
Vesting of restricted and performance stock units (in shares)   287,218            
Shares for acquisition of Fyber (in shares)   5,775,299            
Shares for acquisition of Fyber 356,686       356,686      
Acquisition of non-controlling interests in Fyber 2,578             2,578
Payment of withholding taxes related to the net share settlement of equity awards (8,605)       (8,605)      
Ending balance (in shares) at Mar. 31, 2022   97,163,701 100,000 758,125        
Ending balance at Mar. 31, 2022 $ 516,215 $ 10 $ 100 $ (71) $ 745,661 $ (39,341) $ (191,788) $ 1,644